The study is testing the incidence of MACE and incidence of renal events between Ozempic® users and users with other anti-diabetic medications in T2D patients. This is a retrospective study, and participants had received Ozempic or any other anti-diabetic medications.

Inclusion Criteria:

• Participants had at least one prescription for Ozempic® or other interested anti-diabetic medications during the index identification period.
• Participants had at least one diagnosis of T2D, and had at least one of the three following T2D clinical evidence any time before or on the index date
• Participants had at least 1 all-cause visit record any time after 6 months post-index date.
• At least 18 years old at the index date.

Exclusion Criteria:

• Patients who have used any same anti-diabetic medications as the index treatment within 6 months before index date (e.g., patient prescribed with any Ozempic® during baseline will be excluded if the index drug is a Ozempic®)
• Patients with any diagnosis record of type 1 diabetes or gestational diabetes during whole study period.
• Patients who were pregnant during the whole study period.
• Patients who participated in any clinical trials during the whole study period.
• Patients who were diagnosed with medullary thyroid carcinoma or multiple endocrine neoplasia type II (MEN2) during the whole study period.

Participants received Ozempic (semaglutide) and any other prescribed anti-diabetic medication(s).

According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.